Oculis secures FDA special protocol assessment for Phase 3 trial of optic neuritis treatment

Oculis Holding (NASDAQ:OCS) has received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for its Phase 3 PIONEER-1 trial.

The agreement marks a critical de-risking event for the company's lead candidate, Privosegtor, a potential first-in-class topical treatment for optic neuritis (ON).

The SPA provides official confirmation from the FDA that the PIONEER-1 trial design, endpoints, and statistical analysis are adequate to support a New Drug Application (NDA) submission, provided the study yields positive results.

This regulatory clarity significantly reduces the risk of future disputes regarding the validity of the data during the filing process.

The Phase 3 trial is a registrational study designed to evaluate the efficacy of Privosegtor in patients suffering from acute optic neuritis, a condition often associated with multiple sclerosis that can lead to permanent vision loss.

The primary endpoint of the study is the proportion of patients who gain 15 or more letters in low-contrast visual acuity (LCVA) at the three-month mark.

Participants will be monitored for 12 months to ensure the long-term safety and tolerability of the drug.

The progression into a registrational Phase 3 trial follows strong Phase 2 results from the ACUITY study.

In that trial, Privosegtor demonstrated significant improvements in vision and a favorable safety profile compared to current standards of care, which typically involve high-dose corticosteroids that do not always prevent long-term damage.

Recognizing the high unmet medical need in this space, the FDA previously granted Privosegtor Breakthrough Therapy designation.

The candidate also holds the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) designation, highlighting its potential to offer a major therapeutic advantage over existing treatments.

The receipt of the SPA positions Oculis at the forefront of neuro-ophthalmology innovation.

Optic neuritis currently lacks targeted, non-steroidal therapies, and a successful Phase 3 outcome could establish Privosegtor as the new standard of care.